Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...

There's no escaping the unrelenting passage of time, but supercentenarians who live to see their 110th birthday have a ...

A series of approvals and late-stage regulatory reviews are expanding the use of immunotherapies, antibody-drug conjugates ...

A research collaboration between MIT and Stanford has developed a new approach intended to help the immune system recognise and attack tumours more effectively. Instead of focusing only on protein ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today ...

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

Scientists are increasingly convinced that what happens in the mouth does not stay in the mouth. A growing body of research ...

India's oncology market is shifting to precision medicine as CDSCO approvals expand immunotherapies, ADCs and targeted ...

Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, registrational Phase 3 DIAGNODE-3 trial in type ...

China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...